Icon’s lab services group partners with Cancer Genetics on range of testing services

13-Jul-2015 - Last updated on 14-Jul-2015 at 13:08 GMT

Related tags Pharmacology Clinical trial

DNA-based diagnostics company Cancer Genetics has partnered with the lab services group of CRO Icon to provide clients with new offerings, including oncology-focused genomic testing, central lab analysis, project and data management, and sample logistics.

The companies will look to leverage their expertise to provide insights to the oncology drug development and clinical trial process, particularly around the analysis of lab data from large-scale clinical programmes, as well as through applying genomics and other technologies focused on cancer.

“This partnership will satisfy the enormous need among biotech and pharmaceutical companies for more efficient and comprehensive testing solutions by integrating CGI’s specialized, genomic testing to Icon’s laboratory solutions,” said Panna Sharma, CEO of Cancer Genetics.

The partnership's solution for laboratory testing will be for global oncology trials from Phase I through IV. The companies project that the value of the cancer diagnostics market will reach about $169B globally by 2020, and Cancer Genetics already provides genomic testing for six out of ten major US pharma companies.

James Miskel, EVP of Icon’s Laboratory Services, added: “Together, CGI and Icon are uniquely positioned to provide a full range of comprehensive lab solutions for our customers with current and future oncology focused clinical trials.”